Literature DB >> 11714890

Similar apparent constitutive activity of human histamine H(2)-receptor fused to long and short splice variants of G(salpha).

K Wenzel-Seifert1, M T Kelley, A Buschauer, R Seifert.   

Abstract

Fusion proteins allow for the analysis of receptor/G protein coupling under defined conditions. The beta(2)-adrenoceptor (beta(2)AR) fused to the long splice variant of G(salpha) (G(salphaL)) exhibits a higher apparent constitutive activity than the beta(2)-adrenoceptor fused to the short splice variant of G(salpha) (G(salphaS)). Experimentally, this results in higher efficacy and potency of partial agonists and in higher efficacy of inverse agonists at the beta(2)AR fused to G(salphaL) relative to the beta(2)AR fused to G(salphaS), indicating that the agonist-free beta(2)AR and the beta(2)AR occupied by partial agonists promote GDP dissociation from G(salphaL) more efficiently than from G(salphaS). In fact, the GDP affinity of G(salphaS) fused to the beta(2)AR is higher than the GDP affinity of G(salphaL) fused to the beta(2)AR. We asked the question whether the histamine H(2)-receptor (H(2)R) exhibits similar coupling to G(salpha) splice variants as the beta(2)AR. To address this question, we studied H(2)R-G(salpha) fusion proteins expressed in Sf9 cells. In contrast to beta(2)AR-G(salpha) fusion proteins, the potencies and efficacies of partial agonists and the efficacies of inverse agonists were similar at the H(2)R fused to G(salphaL) and G(salphaS) as assessed by guanosine-5'-O-(3-thio)triphosphate binding and/or steady-state GTPase activity. However, the time course analysis of guanosine-5'-O-(3-thio)triphosphate binding indicated that G(salphaS) fused to the H(2)R possesses a higher GDP-affinity than G(salphaL) fused to the H(2)R. Our data show that the H(2)R fused to G(salphaL) and G(salphaS) possesses similar constitutive activity and is insensitive to differences in GDP affinity of G(salpha) splice variants. Thus, GDP affinity of G proteins does not generally determine constitutive activity of receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714890

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Coupling of beta2-adrenoceptors to XLalphas and Galphas: a new insight into ligand-induced G protein activation.

Authors:  A I Kaya; O Ugur; S S Oner; M Bastepe; H O Onaran
Journal:  J Pharmacol Exp Ther       Date:  2009-01-14       Impact factor: 4.030

Review 2.  International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.

Authors:  Pertti Panula; Paul L Chazot; Marlon Cowart; Ralf Gutzmer; Rob Leurs; Wai L S Liu; Holger Stark; Robin L Thurmond; Helmut L Haas
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

Review 3.  Pharmacological Characterization of Human Histamine Receptors and Histamine Receptor Mutants in the Sf9 Cell Expression System.

Authors:  Erich H Schneider; Roland Seifert
Journal:  Handb Exp Pharmacol       Date:  2017

4.  Point mutations in the second extracellular loop of the histamine H2 receptor do not affect the species-selective activity of guanidine-type agonists.

Authors:  Hendrik Preuss; Prasanta Ghorai; Anja Kraus; Stefan Dove; Armin Buschauer; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

Review 5.  Molecular and cellular analysis of human histamine receptor subtypes.

Authors:  Roland Seifert; Andrea Strasser; Erich H Schneider; Detlef Neumann; Stefan Dove; Armin Buschauer
Journal:  Trends Pharmacol Sci       Date:  2012-12-17       Impact factor: 14.819

Review 6.  Skeletal progenitors and the GNAS gene: fibrous dysplasia of bone read through stem cells.

Authors:  Mara Riminucci; Pamela Gehron Robey; Isabella Saggio; Paolo Bianco
Journal:  J Mol Endocrinol       Date:  2010-09-14       Impact factor: 5.098

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.